Outlook Therapeutics (OTLK) EPS (Basic) (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly EPS (Basic) of -$0.05 for Q1 2026, up 96.38% year-over-year from -$0.03 in Q1 2025, and up 85.79% quarter-over-quarter from -$0.38 in Q4 2025.
Outlook Therapeutics (OTLK) EPS (Basic) (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported EPS (Basic) for 12 consecutive years, with -$0.05 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 96.38% year-over-year to -$0.05; the TTM figure through Mar 2026 stood at -$0.74 (down 208.88% YoY), while the FY2025 annual figure was -$1.79, up 55.85% from the prior year.
- EPS (Basic) rose to -$0.05 in Q1 2026 per OTLK's latest filing, from -$0.38 in the prior quarter.
- Across five years, EPS (Basic) topped out at $1.91 in Q2 2024 and bottomed at -$8.01 in Q1 2024.
- Historically, EPS (Basic) has averaged -$1.08 across 5 years, with a median of -$0.86 in 2023.
- On a YoY basis, EPS (Basic) climbed as much as 218.78% in 2024 and fell as far as 1444.58% in 2024.
- Outlook Therapeutics' EPS (Basic) stood at -$1.64 in 2022, then surged by 47.66% to -$0.86 in 2023, then soared by 183.48% to $0.72 in 2024, then plunged by 153.41% to -$0.38 in 2025, then soared by 85.79% to -$0.05 in 2026.
- Business Quant data shows OTLK's EPS (Basic) at -$0.05 in Q1 2026, -$0.38 in Q4 2025, and -$0.38 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 0.18 |
| 10 | Outlook Therapeutics | 94.49 Mn | 83.25 Mn | -8,265.00 | -0.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05 |
| Dec 31, 2025 | -0.38 |
| Sep 30, 2025 | -0.38 |
| Jun 30, 2025 | -0.55 |
| Mar 31, 2025 | -1.50 |
| Dec 31, 2024 | 0.72 |
| Sep 30, 2024 | 0.31 |
| Jun 30, 2024 | 1.91 |
| Mar 31, 2024 | -8.01 |
| Dec 31, 2023 | -0.86 |
| Sep 30, 2023 | -1.04 |
| Jun 30, 2023 | -1.61 |
| Mar 31, 2023 | -0.52 |
| Dec 31, 2022 | -1.64 |
| Sep 30, 2022 | -1.35 |
| Jun 30, 2022 | -1.59 |
| Mar 31, 2022 | -1.80 |
| Dec 31, 2021 | -1.54 |
| Sep 30, 2021 | -1.76 |
| Jun 30, 2021 | -1.45 |